Best Douglas County Grants for Nonprofits in Oregon

The Porphyrias Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from porphyrias, a group of eight disorders characterized by the accumulation of porphyrins in the body. The fund assists with prescription drug copays and insurance premiums, offering up to $4,000 in financial aid. Established to ensure no patient lacks necessary treatment due to costs, the foundation has awarded over $1.2 billion since 2004, supporting more than 1.1 million patients.

The ACS - Fanconi Cancer Foundation Discovery Boost Grant invites innovative proposals for translational cancer research addressing the challenges faced by individuals with Fanconi anemia (FA). This grant supports high-risk, high-reward projects aimed at improving detection, prevention, or treatment of FA-related cancers. With funding of up to $135,000 per year for two years, it encourages research in early detection technologies, prevention mechanisms, and therapeutic strategies tailored to the unique sensitivities of the FA population.

The Metabolic Dysfunction-Associated Steatohepatitis Fund, established by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients facing chronic illnesses. It provides critical support for expenses related to prescription copays, insurance premiums, and transportation for treatment. With a maximum award of $8,000, the fund ensures that individuals can access necessary healthcare services without financial strain. This initiative emphasizes the commitment to improving health outcomes for those affected by metabolic dysfunction-associated steatohepatitis.

The Mantle Cell Lymphoma Fund, managed by the HealthWell Foundation, provides financial assistance to underinsured patients diagnosed with Mantle Cell Lymphoma. The fund covers prescription drug copays and Medicare Part B premiums, with a maximum award of $8,500. Eligible patients must have insurance that covers their medication and meet specific income guidelines. The foundation aims to reduce financial barriers to essential treatments, ensuring that patients receive necessary care without undue financial strain.

The HealthWell Foundation's Inborn Metabolic or Genetic Bile Acid Deficiency Vitamins and Supplements Fund provides essential financial assistance for individuals facing significant health challenges. By covering copays, deductibles, and related expenses, the fund aims to alleviate the financial burden on underinsured patients. With a commitment to enhancing healthcare access, the Foundation has awarded over $1.2 billion since its inception, ensuring that vital treatments remain accessible to those in need.

The Hyperoxaluria Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from hyperoxaluria, a condition characterized by excessive oxalate in urine. This fund assists with prescription drug copays and insurance premiums, providing vital support for treatments. In 2024 alone, HealthWell allocated over $1.2 billion in grants, ensuring access to essential medications for those in need. The organization is committed to improving healthcare access and reducing disparities for affected individuals.

The Emergency/Medical Workers Behavioral Health Fund aims to support emergency workers facing trauma and anxiety due to their roles. Established by the HealthWell Foundation, it provides financial assistance for treatment-related costs, including copayments for prescription drugs, counseling, and transportation. In 2024, the Foundation awarded over $1.2 billion to underinsured patients, ensuring no one is denied essential healthcare due to financial barriers. This initiative helps address the critical mental health needs of those who serve on the front lines.

The Dupuytren’s Disease Fund, managed by the HealthWell Foundation, aims to reduce financial barriers for underinsured patients suffering from Dupuytren's Disease. This fund provides assistance for prescription drug copays and insurance premiums related to treatment. With an average grant utilization of $1,650 over a 12-month period, the fund ensures that essential medications and therapies are affordable. HealthWell Foundation, a private non-profit, has helped over 1.1 million patients since 2004, demonstrating its commitment to healthcare access.

The Cushing's Disease or Cushing's Syndrome Fund, operated by the HealthWell Foundation, provides vital financial assistance to underinsured patients facing high medical costs associated with these conditions. The fund covers co-payments, insurance premiums, and necessary treatments, ensuring that patients receive the care they need without financial burden. With an average grant utilization of $3,000 over twelve months, this fund aims to alleviate the challenges of treatment accessibility, supporting both physical and mental health for those affected.

The Congenital Sucrase-Isomaltase Deficiency Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from this genetic disorder. By providing assistance with prescription drugs and treatment costs, the fund ensures that vital medications are accessible, allowing patients to manage their condition effectively. In 2024, the Foundation is expected to award over $1.2 billion in grants, showcasing its commitment to enhancing healthcare access for those in need.

The Chronic Lymphocytic Leukemia Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients battling chronic lymphocytic leukemia (CLL). This fund provides essential support for prescription copays and premiums, ensuring that patients can access necessary treatments without the stress of financial constraints. Since its inception, the foundation has awarded over $1.2 billion in grants, helping more than 1.1 million patients. The initiative emphasizes the importance of accessible healthcare and aims to improve the quality of life for those affected by this condition.

The Cancer-Related Behavioral Health Fund, established by the HealthWell Foundation, provides financial assistance to individuals diagnosed with cancer for behavioral health treatments. This fund covers costs associated with prescription drugs, counseling services, and transportation. Aiming to alleviate financial burdens, it ensures that underinsured patients can access necessary care without delay. In 2024, the foundation awarded over $1.2 billion, emphasizing its commitment to improving health outcomes for cancer patients across the United States.

The Blepharitis Fund, managed by the HealthWell Foundation, aims to alleviate financial barriers for underinsured patients suffering from blepharitis, an inflammatory condition of the eyelids. This program assists with prescription drug copays and insurance premiums, covering up to $3,500 annually for treatments. With a mission to ensure no patient is deprived of necessary healthcare due to financial constraints, the HealthWell Foundation has provided over $1.2 billion in grants, supporting more than 1.1 million patients since its inception.

The ANCA-Assoc Vasculitis and Granulomatosis with Polyangiitis Fund, established by the HealthWell Foundation, aims to reduce financial barriers for underinsured patients suffering from this rare and serious condition. The fund assists with copays, premiums, and out-of-pocket expenses related to treatment, ensuring that affected individuals have access to necessary medications. With over $1.2 billion in grants awarded since 2004, the foundation has helped over 1.1 million patients access critical healthcare services.

The Amyotrophic Lateral Sclerosis Fund, managed by HealthWell Foundation, aims to alleviate financial barriers for underinsured patients battling ALS, a progressive neurodegenerative disease. The fund provides financial assistance for prescription copays, insurance premiums, and related healthcare expenses, ensuring patients can access vital treatments. With an average grant utilization of $3,000 over twelve months, the fund exemplifies HealthWell's commitment to ensuring no patient is denied necessary healthcare due to cost. Since 2004, HealthWell has awarded over $1.2 billion in grants, supporting more than 1.1 million patients.

The Amyloidosis Fund, managed by the HealthWell Foundation, provides essential financial assistance to underinsured patients facing treatment costs for Amyloidosis. The program covers prescription copays, insurance premiums, and related expenses, ensuring that patients can access necessary medications without financial strain. With a maximum award of $8,000, the fund aims to alleviate the burden of healthcare costs for those diagnosed with this complex disease, promoting better health outcomes and quality of life for patients across the United States.

The Alagille Syndrome Vitamins and Supplements Fund, managed by the HealthWell Foundation, offers financial assistance to patients suffering from Alagille Syndrome. This fund helps cover the costs of essential vitamins and supplements needed for treatment. With a maximum award of $1,500, the program aims to reduce financial barriers for underinsured individuals, ensuring they receive the necessary support to manage their health, thereby enhancing their quality of life.

The Philip J. Wyatt Award in Analytical Chemistry, established in 1947 and endowed by the Wyatt Family Foundation in 2026, recognizes outstanding contributions to analytical chemistry. Offered by the American Chemical Society, the award includes a $5,000 prize and a certificate, with up to $2,500 for travel expenses to the award presentation meeting. This award supports diversity and inclusion by being available regardless of race, gender, or background, promoting a global community in the field of chemistry.

The Abbvie Parkinson’s Disease Grant aims to enhance the understanding and management of subcutaneous infusion therapies for advanced Parkinson’s disease. As these therapies become more prevalent, it is crucial for Movement Disorder Specialists and General Neurologists to develop confidence in identifying, mitigating, and managing infusion site events. This grant seeks to provide essential education and resources to support safe and effective treatment options for patients experiencing motor fluctuations.

The BioMarin Grant aims to support events, activities, and projects that enhance public health and benefit patients with rare diseases. This corporate funder focuses on scientific innovation and provides resources for organizations such as hospitals, universities, and patient advocacy groups. With an emphasis on education and community support, BioMarin encourages applications for funding throughout the year, ensuring timely assistance for eligible projects.

The BioMarin Medical Education Grant offers funding for educational activities aimed at enhancing the knowledge and skills of healthcare professionals. Eligible applicants include accredited providers, medical associations, and patient advocacy groups. The grant focuses on supporting initiatives related to rare diseases, ensuring timely access to treatments and education. Applications are accepted year-round, but a minimum of 60 days is required for review prior to events. This commitment underscores BioMarin's dedication to improving patient care and advancing medical knowledge.

BioMarin offers funding through its donation program focused on improving healthcare and patient advocacy, particularly for rare diseases. Organizations eligible for support include hospitals, accredited providers, and patient advocacy groups. BioMarin prioritizes innovative therapeutic solutions for rare genetic conditions. The company is dedicated to enhancing patient care and education, and it reviews funding requests year-round, although specific deadlines apply for year-end funding. This initiative reflects BioMarin's commitment to addressing unmet medical needs.

The Strategic Projects: Capital Grants by the M J Murdock Charitable Trust offer vital funding opportunities for nonprofit organizations in the Pacific Northwest. These grants support transformative projects that enhance community well-being through construction, renovation, and infrastructure investments. Eligible entities include 501(c)(3) nonprofits and government entities. The Trust emphasizes projects that demonstrate strong community impact and funding diversification, ensuring sustainable growth and lasting benefits for the communities served.

The M J Murdock Charitable Trust offers Strategic Projects: Equipment & Technology Grants to nonprofits in the Pacific Northwest. These grants focus on capacity-building projects and essential equipment, requiring recipients to cover at least 50% of costs. Eligible organizations include 501(c)(3) nonprofits and tribal entities. Priority is given to projects enhancing community services, education, and environmental stewardship, supporting initiatives that foster human flourishing and demonstrate diversified funding.

The Society of Family Planning is offering the Bridging Investments in Abortion and Contraception Research Grant to support the completion of NIH grants focused on abortion and contraception. This funding aims to mitigate the impact of recent funding terminations by ensuring that vital research continues, promoting equitable access to reproductive health. Proposals can request up to $100,000 and must detail their alignment with the Society's mission, planned activities, and budget within a 24-month timeline.

The Slomo and Cindy Silvian Foundation Grant supports a range of subjects including education, children's welfare, medical care, medical research, and Jewish philanthropic endeavors. Established in honor of Cindy Silvian, the foundation has awarded over $30 million since 2008. Applications are by invitation only, and organizations must meet specific eligibility criteria to be considered for funding. This year, the foundation allocated over $2.4 million to more than 110 organizations, highlighting its commitment to impactful philanthropy.

The Avant Garde Award supports innovative research on HIV and substance use disorders, encouraging creative scientists to explore high-risk, high-reward approaches. While applications are not currently being accepted, this initiative by the National Institute on Drug Abuse (NIDA) aims to stimulate collaborations and impactful research. Early-stage investigators are particularly encouraged to consider this opportunity as they develop their proposals for future funding. The program uses the DP1 activity code, fostering transformative advancements in biomedical and behavioral science.